Outcomes of patients with localized prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy boost: A single-center retrospective study

[1] Bergengren O, Pekala KR, Matsoukas K et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. Eur Urol 2023; 84: 191–206. BergengrenO PekalaKR MatsoukasK 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review Eur Urol 2023 84 191 206 Search in Google Scholar

[2] Mendez LC, Morton GC. High dose-rate brachytherapy in the treatment of prostate cancer. Transl Androl Urol 2018; 7: 357–70. MendezLC MortonGC High dose-rate brachytherapy in the treatment of prostate cancer Transl Androl Urol 2018 7 357 70 Search in Google Scholar

[3] Georg D, Hopfgartner J, Gòra J et al. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2014; 88: 715–22. GeorgD HopfgartnerJ GòraJ Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy Int J Radiat Oncol Biol Phys 2014 88 715 22 Search in Google Scholar

[4] Spratt DE, Scala LM, Folkert M et al. A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer. Brachytherapy 2013; 12: 428–33. SprattDE ScalaLM FolkertM A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer Brachytherapy 2013 12 428 33 Search in Google Scholar

[5] Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 1095–101. BrennerDJ HallEJ Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 1999 43 1095 101 Search in Google Scholar

[6] Brenner DJ, Martinez AA, Edmundson GK et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002; 52: 6–13. BrennerDJ MartinezAA EdmundsonGK Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue Int J Radiat Oncol Biol Phys 2002 52 6 13 Search in Google Scholar

[7] Vogelius IR, Bentzen SM. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 2013; 85: 89–94. VogeliusIR BentzenSM Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 2013 85 89 94 Search in Google Scholar

[8] Martinez AA, Gonzalez J, Ye H, et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79: 363–370. MartinezAA GonzalezJ YeH Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy Int J Radiat Oncol Biol Phys 2011 79 363 370 Search in Google Scholar

[9] Kishan AU, Cook RR, Ciezki JP et al. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9–10 Prostate Cancer. Jama 2018; 319: 896–905. KishanAU CookRR CiezkiJP Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9–10 Prostate Cancer Jama 2018 319 896 905 Search in Google Scholar

[10] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2023 https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Search in Google Scholar

[11] D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 1998; 280: 969–74. D’AmicoAV WhittingtonR MalkowiczSB Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer Jama 1998 280 969 74 Search in Google Scholar

[12] Harris VA, Staffurth J, Naismith O et al. Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 2015; 92: 874–83. HarrisVA StaffurthJ NaismithO Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy Int J Radiat Oncol Biol Phys 2015 92 874 83 Search in Google Scholar

[13] Morton G, Loblaw A, Cheung P et al. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother Oncol 2011; 100: 463–7. MortonG LoblawA CheungP Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother Oncol 2011 100 463 7 Search in Google Scholar

[14] Hoskin PJ, Colombo A, Henry A et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol 2013; 107: 325–32. HoskinPJ ColomboA HenryA GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update Radiother Oncol 2013 107 325 32 Search in Google Scholar

[15] Roach M, 3rd, Hanks G, Thames H et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965–74. RoachM3rd HanksG ThamesH Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 2006 65 965 74 Search in Google Scholar